Capio Diagnostics

Capio Biosciences is a biotechnology company focused on developing high-sensitivity liquid biopsy technologies for cancer diagnostics. The company's core platform, CapioCyte, utilizes a biomimetic approach that combines cell-size-dependent capture and multivalent binding to isolate circulating tumor cells (CTCs) from whole blood with high efficiency and purity. This technology enables early cancer detection, treatment monitoring, and personalized medicine by providing a non-invasive alternative to traditional tissue biopsies. By leveraging microfluidics and nanotechnology, Capio Biosciences aims to facilitate better molecular profiling of tumors through a simple blood draw. The company's products are designed to assist clinicians in making more informed decisions throughout the patient's oncology journey.